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Growth and weight gain in children with
juvenile idiopathic arthritis: results from the
ReACCh-Out cohort
Jaime Guzman1,19* , Tristan Kerr19, Leanne M. Ward10, Jinhui Ma10, Kiem Oen6, Alan M. Rosenberg5,
Brian M. Feldman9, Gilles Boire14, Kristin Houghton1, Paul Dancey17, Rosie Scuccimarri11, Alessandra Bruns14,
Adam M. Huber16, Karen Watanabe Duffy10, Natalie J. Shiff18, Roberta A. Berard7, Deborah M. Levy9,
Elizabeth Stringer16, Kimberly Morishita1, Nicole Johnson4, David A. Cabral1, Maggie Larché8, Ross E. Petty1,
Ronald M. Laxer9, Earl Silverman9, Paivi Miettunen4, Anne-Laure Chetaille15, Elie Haddad12, Lynn Spiegel9,
Stuart E. Turvey1, Heinrike Schmeling4, Bianca Lang16, Janet Ellsworth3, Suzanne E. Ramsey16, Johannes Roth10,
Sarah Campillo11, Susanne Benseler4, Gaëlle Chédeville11, Rayfel Schneider9, Shirley M. L. Tse9, Roxana Bolaria2,
Katherine Gross2, Debbie Feldman13, Bonnie Cameron9, Roman Jurencak10, Jean Dorval15, Claire LeBlanc11,
Claire St. Cyr12, Michele Gibbon10, Rae S. M. Yeung9, Ciarán M. Duffy10 and Lori B. Tucker1

Abstract
Background: With modern treatments, the effect of juvenile idiopathic arthritis (JIA) on growth may be less than
previously reported. Our objective was to describe height, weight and body mass index (BMI) development in a
contemporary JIA inception cohort.
Methods: Canadian children newly-diagnosed with JIA 2005–2010 had weight and height measurements every
6 months for 2 years, then yearly up to 5 years. These measurements were used to calculate mean age- and
sex-standardized Z-scores, and estimate prevalence and cumulative incidence of growth impairments, and the impact
of disease activity and corticosteroids on growth.
Results: One thousand one hundred forty seven children were followed for median 35.5 months. Mean Z-scores, and the
point prevalence of short stature (height < 2.5th percentile, 2.5% to 3.4%) and obesity (BMI > 95th percentile, 15.8% to 16.
4%) remained unchanged in the whole cohort. Thirty-three children (2.9%) developed new-onset short stature, while 27
(2.4%) developed tall stature (>97.5th percentile). Children with systemic arthritis (n = 77) had an estimated 3-year
cumulative incidence of 9.3% (95%CI: 4.3–19.7) for new-onset short stature and 34.4% (23–49.4) for obesity. Most children
(81.7%) received no systemic corticosteroids, but 1 mg/Kg/day prednisone-equivalent maintained for 6 months
corresponded to a drop of 0.64 height Z-scores (0.56–0.82) and an increase of 0.74 BMI Z-scores (0.56–0.92). An increase
of 1 in the 10-cm physician global assessment of disease activity maintained for 6 months corresponded to a drop of 0.01
height Z-scores (0–0.02).
Conclusions: Most children in this modern JIA cohort grew and gained weight as children in the general population.
About 1 in 10 children who had systemic arthritis, uncontrolled disease and/or prolonged corticosteroid use, had
increased risk of growth impairment.
Keywords: Juvenile arthritis, Growth, Obesity, Corticosteroids
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Background
Juvenile idiopathic arthritis (JIA) is the most common
rheumatic disease of childhood [1], and the seven JIA
categories have different characteristics and outcomes
[2, 3]. Chronic inflammation in children with JIA may
lead to growth delay and poor weight gain, while use of
corticosteroids to control inflammation may lead to
growth delay and excessive weight gain. Our knowledge
about growth in children with JIA is largely based on
older cross-sectional studies and retrospective cohorts
from single centres [4, 5]. These studies included 20 to
200 children each and reported frequent growth impairments (a deviation from healthy growth standards in
height, weight or body mass index, BMI) [5]. More recently, synthetic disease-modifying antirheumatic drugs
(DMARDS) and biologic medications, which help control
inflammation and reduce the need for corticosteroids,
have been reported to mitigate growth impairment [6–9].
Yet, as recently as 2011, significant height growth delay
was reported in oligoarthritis, a usually mild JIA category
rarely treated with systemic corticosteroids [10].
In this study, we used data from a prospective multicentre inception cohort of over one thousand Canadian
children to determine 1) height, weight and BMI trajectories over time in children with JIA managed with modern
treatments; 2) their risk of growth impairments; and 3) the
impact of disease activity and corticosteroid use on growth.
Methods
Subjects

Data from the Research in Arthritis in Canadian Children
emphasizing Outcomes (ReACCh-Out) cohort were used.
ReACCh-Out was designed to document disease outcomes in usual practice [3, 11]. It enrolled 1497 patients
newly diagnosed with JIA between 2005 and 2010 at all 16
Canadian pediatric rheumatology centres. JIA category
was assigned using accepted criteria within 6 months of
enrolment [2, 3]. Study visits were scheduled at enrolment
and at 6, 12, 18, 24, 36, 48, and 60 months thereafter. The
study was approved by research ethics boards at each participating institution. Parents provided informed written
consent, and patients provided assent where appropriate.
This report includes children recruited within 6 months
of diagnosis who had at least two available height and
weight records as of May 30th, 2012.
Measures of growth and weight gain

Standing height and weight were measured at each study
visit as per usual clinic practices. We calculated age- and
sex-standardized scores (Z-scores, 0 = mean of healthy
children, 1 = one standard deviation in healthy children)
[12], for height, weight, and BMI for each child using standards for healthy growth endorsed by the Canadian
Pediatric Endocrinology Group [13]. These are equivalent
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to the 2007 World Health Organization standards, except
that standards for both weight and BMI are provided up
to age 18 years [14].
Growth impairments were defined as follows:
Short stature: a height below the 2.5th percentile for
age and sex (corresponding to a Z-score < −2.0) [15].
Tall stature: a height above the 97.5th percentile for
age and sex.
Obesity: a BMI above the 95th percentile for age and
sex [12].
Thinness: a BMI below the 5th percentile for age and
sex.
Growth delay: a decrease of 1.0 or more in height Zscore at a given visit, relative to the Z-score of that child
at enrolment.
Growth acceleration: an increase of 1.0 or more in
height Z-score at a given visit, relative to the Z-score of
that child at enrolment.
Excessive weight gain: an increase of 1.0 or more in
BMI Z-score at a given visit, relative to the Z-score of
that child at enrolment.
Poor weight gain: a decrease of 1.0 or more in BMI Zscore at a given visit, relative to the Z-score of that child
at enrolment.
These definitions and cut-offs have been used in previous studies, but they are not universally accepted. The Zscore at enrolment was calculated using the first available
measurements of height and weight (a median of
0.5 months after diagnosis), representing our best estimate
of the child’s baseline growth. A change of 1.0 Z-scores
from enrolment was chosen because it roughly corresponds to the crossing of a percentile channel on growth
charts [16], and it had been used in a previous study [10].

Other measures

Disease activity and medication use were recorded at each
study visit, and at clinic visits in-between study visits. Disease activity was reported by the pediatric rheumatologist
using a standard 10-cm horizontal visual analogue scale
from 0 = inactive disease to 10 = very active disease [17].
Early treatment responders (versus non-early responders)
were defined as those who attained clinically inactive disease within a year of diagnosis [3, 17].
The name and current dose of oral and intravenous corticosteroids recorded at each clinic visit were used to calculate mg/kg/day in prednisone equivalent using published
conversion factors [18, 19], and the most recently recorded
patient’s weight. Children were categorized as non-users of
systemic corticosteroids, transitory users (3 months or less)
or prolonged users (>3 months of cumulative use during
the study), irrespective of the doses or frequency of administration; intraarticular corticosteroid administration was
not considered in this categorization.
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The education level of the parent with the highest level
of education was used as a proxy for socio-economic
status and self-reported ethnicity was recorded using
Statistics Canada standard categories.
Statistical analysis

Analyses were conducted using STATA 12 software [StataCorp LP, College Station, Texas]. Trajectories of the
mean Z-score over time were charted using locally
weighted scatter plot smoothing with a band width of 0.6
to produce lines reflecting observed data without imposing a particular shape. Kaplan Meier survival methods
were used to estimate the cumulative incidence of newonset growth impairments. These consider only the first
occurrence of growth impairment, and do not reflect persistence or resolution of the impairment. Because the
number of subjects in some JIA categories was small beyond three years, we show plots only to three years after
diagnosis. The log-rank test was used to compare survival
curves. Mixed effects models assessed the impact of cumulative disease activity and corticosteroid use in the previous six months on Z-scores, after adjusting for parental
education, ethnicity and JIA category. Models were implemented in STATA as growth curve models [20] with random intercept, random slope and a quadratic term for
time since diagnosis (see Additional file 1 for details).
Sensitivity analyses to assess the robustness of our findings included use of alternative growth charts and measures of disease activity [21], analyses in children of prepubertal age (defined as <7 years at diagnosis) and calculation of cumulative incidence of reciprocal “growth impairments” (e.g. tall stature and growth acceleration) to assess
to what extent our results were due to normal variability
and the choice of cut-off, rather than true impairments.

Results
A total of 1147 children were included (Table 1). The reasons for ineligibility and subject disposition are shown in
Fig. 1. The median age at diagnosis was 9.5 years (25th,
75th centile: 4, 13) and 64% were female. The median time
from diagnosis to enrolment was 0.5 months (0, 1.9).
Height and weight measurements were available on 5909
visits for a median follow-up of 35.5 months (25th, 75th
centile: 23, 49). Additional file 1: Table S1 shows subjects
with data at each visit.
Height, weight and BMI trajectories

Figure 2 shows trajectories of height, weight, and BMI
mean Z-scores for the whole cohort and for each JIA category. Mean height Z-scores remained unchanged for the
whole cohort (Fig. 2d). Children with enthesitis-related
arthritis had an estimated mean height Z-score at diagnosis
of +0.2 and remained unchanged over 3 years. In contrast,
children with systemic arthritis also had an estimated mean
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height Z-score at diagnosis of +0.2 but it decreased and did
not return to baseline within 3 years. Using quadratic fit
equations the corresponding 95% CI become nonoverlapping by one year (Additional file 1: Fig. S1).
Mean weight and BMI Z-scores in the whole cohort
and in the most frequent JIA categories (oligoarthritis,
RF-negative polyarthritis, enthesitis-related, undifferentiated) remained stable over time (Fig. 2). These parameters increased during the first year after diagnosis in
children with systemic JIA and RF-positive polyarthritis,
but their estimates at diagnosis were different: a mean
BMI Z-score of +0.6 for systemic and −0.1 for RFpositive polyarthritis. Mean values of weight and BMI Zscores of children with psoriatic arthritis were high at
enrolment and decreased over time.
Growth impairments

The point prevalence of short stature in the whole cohort
remained stable during the study (2.5 to 3.4%, Fig. 3).
Thirty-three children (2.9%) had new-onset short stature
(<2.5th percentile), while 27 (2.4%) had new-onset tall
stature (>97.5th percentile) during the study. Ninety-three
children (8.1%) had growth delay, while 64 (5.6%) had
growth acceleration. The estimated cumulative incidence
of growth delay within 3 years of diagnosis for the whole
cohort was 8.5% (95%CI: 6.8–10.6, Table 2). It varied from
5.7% to 9.9% across JIA categories, except for systemic
arthritis (22.5%, 14.2–34.7).
The point prevalence of obesity in the whole cohort
remained stable during the study (15.8 to 16.8%, Fig. 3).
Ninety-seven children (8.5%) developed new onset obesity,
while 43 (3.7%) developed new onset thinness. The estimated cumulative incidence of obesity within three years
of diagnosis was 10.8% (95%CI: 8.8–13.2, Table 2); it varied
from 5.9% to 14.1% across JIA categories, except for systemic arthritis (34.4%, 23.0–49.4). The estimated cumulative incidence of excessive weight gain within 3 years of
diagnosis varied from 5% to 15% across JIA categories, except for systemic arthritis (28.1%, 19.0–40.3).
Impact of corticosteroids and disease activity

In adjusted mixed effects models, a dose of 1 mg/kg/day
prednisone equivalents maintained for 6 months corresponded to a decrease of 0.64 in height Z-scores (95%CI:
0.56–0.82) and an increase of 0.74 in BMI Z-scores (0.56–
0.92) (Table 3). Additional file 1: Fig. S2 shows trajectories
of mean corticosteroid dose for each JIA category. Most
children received no systemic corticosteroids during the
study (n = 943, 81.7%), while 88 (7.6%) were transitory
users and 123 (10.6%) were prolonged users (>3 months).
The estimated cumulative incidence of short stature
among prolonged corticosteroid users was 6.6% within
3 years, compared to 2.6% for non-users (p = 0.07, logrank test for survival curves). The estimated cumulative
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Table 1 Characteristics of patients by JIA categorya
Characteristic

All
(N = 1147)

Systemic
Arthritis
(n = 77)

Oligoarthritis RF-negative RF-positive Psoriatic
(n = 443)
polyarthritis polyarthritis arthritis
(n = 232)
(n = 44)
(n = 70)

Enthesitis-related Undifferentiated
Arthritis (n = 164) (n = 117)

% Female

64.0

47.4

70.2

77.6

95.5

67.1

25.0

68.4

Age at
diagnosis (yrs)

9.5
(4.0, 13.1)

6.6
(3.1, 12.2)

6.4
(3.0, 11.5)

9.1
(3.4, 12.7)

12.8
(9.4, 15.2)

11.6
(5.3, 13.6)

13.1 (10.8,14.5)

9.5 (3.7, 13.1)

Disease duration
(months)

5.8
(3.1, 10.9)

2.9
(1.9, 5.4)

5.3
(3.0, 8.9)

6.1
(3.4, 12.4)

5.5
(3.6, 10.6)

6.5
(3.0, 13.6)

8.9 (4.2,17.3)

5.9 (3.5, 9.0)

Follow-up
(months)

35.5
(23,49)

40.7
(24,52)

35.0
(23,49)

36.7
(24,52)

33.1
(23, 49)

34.5
(18, 49)

30.9 (19, 40)

35.7 (23, 48)

Height Z-score
at enrolment

0.02
(−0.70, 0.82)

0.09
0.06
(−0.69, 0.91) (−0.65, 0.83)

−0.13
0.02
0.12
0.16 (−0.52, 0.98)
(−0.77, 0.58) (−0.59, 0.69) (−0.68, 0.99)

−0.19
(−0.92, 0.62)

Weight Z-score
at enrolment

0.31
(−0.37, 1.06)

0.58
(0.04, 1.25)

0.25
(−0.35, 0.90)

0.17
0.16
0.66
(−0.53, 0.94) (−0.83, 0.94) (−0.26, 1.4)

0.61 (−0.52, 1.4)

0.29
(−0.53, 0.96)

BMI percentile
at enrolment

66
(34, 89)

80.4
(62, 90)

62.6
(35, 87)

64.6
(34, 87)

55.8
(18, 88)

75.3
(46, 96)

65.8 (28, 93)

67.0 (38, 88)

Disease activity
(mm)

28 (12, 50)

37 (13, 62)

19 (8, 34)

46 (27, 66)

52 (26, 71)

23 (11, 51)

30 (12, 46)

26 (12, 48)

ESR, mm/hb

18 (7, 36)

58 (25, 89)

17 (7, 31)

18 (8, 36)

36 (16, 53)

15 (8, 36)

10 (4, 24)

16 (5, 35)

55.7

71.1

33.9

84.9

97.7

50.0

58.7

53.8

c

Treatments

DMARDs (%)
Biologics (%)

11.7

34.2

3.6

15.9

40.9

7.1

12.2

10.3

Corticosteroid
joint injections (%)

44.3

17.1

55.5

43.5

43.2

41.4

31.4

41.9

Systemic corticosteroids
(%)

18.2

85.5

9.3

28.0

63.6

17.1

23.8

23.1

Corticosteroids >3
months (%)

10.6

65.0

0.9

10.8

29.5

2.9

9.3

11.1

British (%)

50.2

41.9

44.7

54.1

44.2

60.6

54.6

53.5

French (%)

31.2

22.1

35.8

26.1

18.6

34.8

22.7

42.1

Indigenous
Canadian (%)

8.1

5.8

8.9

7.7

16.3

6.1

5.5

8.8

Other (%)

25.4

26.7

21.8

31.5

34.9

16.7

30.7

16.7

Less than high
school (%)

2.01

1.6

1.9

2.9

0

1.6

2.6

1.0

High school/
some
postsecondary (%)

50.24

53.1

45.8

51.7

61.9

54.1

51.6

56.4

University/
postgraduate
degree (%)

47.75

45.3

51.6

46.4

38.1

44.3

45.8

42.6

49.5

44.7

65.48

36.6

22.7

42.9

37.8

39.3

Ethnicityd

Parental educatione

Inactive disease
within 1 year of
diagnosis (%)
a

Numbers are median and (25th, 75th centiles) unless otherwise specified
ESR was obtained in 88% of the cohort at enrolment
c
Treatments received at any time during the study
d
Self-reported ethnicity was available in 96% of the cohort. Other ethnicity includes Asian, African, Latin American and other European ethnicities. The sum of
ethnicities may add to more than 100% because each child could report up to 6 ethnic backgrounds
e
The level of education of the parent who had a higher level of education. Parental education for at least one parent was obtained in 93% of the cohort
at enrolment
b
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file 1: Table S3 and suggest a substantial portion of the
incidence of growth impairments reported in Table 2 is
due to normal variability and our choice of cut-offs rather than to the disease; for example, the 3-year cumulative incidence of tall stature for the whole cohort was
2.3%, compared to 3.0% for short stature. Children
younger than 7 years at diagnosis had higher cumulative
incidence of growth impairments, relative to the whole
cohort, and a different distribution of JIA categories
(Additional file 1: Table S4). Use of the active joint count
or the Juvenile Arthritis Disease Activity Score [21], as
alternative measures of disease activity, did not substantially change our findings (Additional file 1: Table S5).

Fig. 1 Subject eligibility and disposition

incidence of obesity among prolonged corticosteroid users
was 25% within 3 years, compared to 8.5% for non-users
(p < 0.0001, log-rank test for survival curves, Additional
file 1: Fig. S3).
In adjusted models, a 1 cm increase in the 10 cm
physician global assessment of disease activity maintained for 6 months was associated with a decrease of
0.01 in height Z-scores (95%CI: 0.00–0.02) (Table 3).
The association between disease activity and changes in
BMI Z-scores was not significant. Mean disease activity
decreased in all JIA categories after diagnosis (Additional
file 1: Fig. S2) and 567 children (49.5%) attained inactive
disease within the first year. Early treatment responders
and non-early treatment responders had similar probability of growth impairments (Additional file 1: Fig. S4).
Sensitivity analyses

Using the Centers for Disease Control growth charts
had minimal impact on our estimates of growth impairments, except for a lower cumulative incidence of obesity within 3 years of diagnosis of 7.5% (95%CI: 5.9–9.6)
(Additional file 1: Table S2). Calculations for reciprocal
“growth impairments” (growth acceleration, tall stature,
poor weight gain and thinness) are shown in Additional

Discussion
We used data from a large prospective inception cohort
of Canadian children with JIA to estimate impact of the
disease and its treatment on height, weight and BMI development. For children in the most frequent JIA categories
(oligoarthritis,
RF-negative
polyarthritis,
enthesitis-related arthritis and undifferentiated arthritis,
83.5% of the cohort) the impact was negligible. On the
other hand, children with systemic arthritis showed a decrease in height Z-scores and increase in BMI Z-scores,
with no apparent return to baseline within 3 years. To
put things in perspective, the decrease in mean height
Z-scores in children with systemic JIA corresponds to
approximately 2 cm for a 9 year old child. Children with
RF-positive polyarthritis or psoriatic arthritis had relatively minor, but measurable, risk of growth impairments. For the whole cohort, point prevalence for short
stature and obesity remained unchanged over the 3 years
after diagnosis, suggesting the observed growth impairments affected too few children and/or were too shortlived to affect the overall prevalence.
Most children received no systemic corticosteroids, in
those who did, larger doses of corticosteroids were clearly
associated with lower height and higher BMI Z-scores. A
similar impact of corticosteroids on BMI has been shown
in children with a variety of rheumatic diseases [22]. In
our cohort, most children with systemic JIA received
high-dose corticosteroids, which likely mediated their observed growth impairments. Increased disease activity was
associated with lower height Z-scores but the impact was
minor, relative to that of corticosteroids.
Our original protocol considered a change of 1.0 Zscores relative to baseline indicative of growth impairment
because this roughly corresponds to crossing a percentile
channel in growth charts [16], and it had been used in a
previous study [10]. However, we later realized this definition may lead to apparent growth impairments even in
healthy children. Growth in healthy children is complex
and may have periods of relative stasis or rapid growth
[23]. This may result in apparent delay or acceleration of
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a

b

c

d

Fig. 2 Smoothed trajectories of mean Z-scores. Shown are trajectories of (a) height, (b) weight, and (c) BMI for each JIA category in the 3 years
after diagnosis. Panel (d) shows Z-score trajectories for the whole cohort. Trajectories of the mean Z-score were charted using locally weighted
scatter plot smoothing with a band width of 0.6. The black dashed horizontal line represents healthy growth standards

growth when comparing a child to normative growth
curves [12]. For example, children with enthesitis-related
arthritis in our cohort had a virtually flat trajectory of
mean height Z-score (i.e. they grew at the same pace than
healthy children), but over 3 years they still had a 7.2%

a

cumulative incidence of growth delay and a 7.7% cumulative incidence of growth acceleration. We believe cumulative incidences of this level using the 1.0 Z-score cut-off
likely reflect normal periods of relative stasis or rapid
growth, rather than true growth impairments. This could

b

Fig. 3 Point prevalence of short stature and obesity in the whole cohort. Shown are the point prevalences of a) short stature and b) obesity in
the whole cohort at every study visits for the 3 years after enrolment, and after excluding children who received corticosteroids. The vertical lines
represent 95%CI
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Table 2 Estimates of the cumulative incidence (%) of growth delay, short stature, excessive weight gain and obesity within 1 and
3 years after diagnosis in seven JIA categories
JIA Category

Growth delay

Short stature

Excessive weight gain

Obesity

1-year
cumulative
incidence
(95% CI)

3-year
cumulative
incidence
(95% CI)

1-year
cumulative
incidence
(95% CI)

3-year
cumulative
incidence
(95% CI)

1-year
cumulative
incidence
(95% CI)

3-year
cumulative
incidence
(95% CI)

1-year
cumulative
Incidence
(95% CI)

3-year
cumulative
Incidence
(95% CI)

All (N = 1147)

3.2 (2.4, 4.5)

8.5 (6.8, 10.6)

1.2 (0.7, 2.1)

3.0 (2.1, 4.4)

4.8 (3.7, 6.2)

10.7 (8.8, 12.9)

5.2 (4.0, 6.9)

10.8 (8.8, 13.2)

Systemic
arthritis
(n = 77)

6.8 (2.9, 15.7) 22.5 (14.2, 34.7) 1.4 (0.2, 9.8)

9.3 (4.3, 19.7) 17.2 (10.4, 27.8) 28.1 (19.0, 40.3) 22.7 (13.9, 35.9) 34.4 (23.0, 49.4)

Oligoarthritis
(n = 443)

3.8 (2.3, 6.1)

7.8 (5.3, 11.3)

1.2 (0.5, 2.9)

2.3 (1.2, 4.4)

3.8 (2.3, 6.1)

10.5 (7.6, 14.4)

3.3 (1.9, 5.7)

8.2 (5.5, 12.1)

RF-negative
polyarthritis
(n = 232)

4.0 (2.1, 7.6)

7.4 (4.5, 12.0)

0.9 (0.2, 3.6)

0.9 (0.2, 3.6)

3.6 (1.8, 7.0)

8.9 (5.6, 14.1)

3.5 (1.7, 7.2)

8.5 (5.2, 13.8)

RF-positive
polyarthritis
(n = 44)

—

9.9 (3.1, 28.7)

—

4.3 (0.6, 27.1) 9.1 (3.5, 22.6)

15.0 (7.2, 31.9)

—

5.9 (0.8, 35.0)

Psoriatic
arthritis
(n = 70)

2.9 (0.7, 10.9) 9.5 (4.0, 21.8)

2.9 (0.7, 11.1) 9.5 (3.9, 22.0) 3.0 (0.7, 11.4)

5.0 (1.6, 14.9)

4.1 (1.0, 15.5)

11.7 (5.0, 26.0)

Enthesitis-related 1.2 (0.3, 4.7)
arthritis
(n = 164)

7.2 (3.6, 14.4)

0.6 (0.1, 4.5)

1.6 (0.4, 6.3)

3.7 (1.7, 8.1)

8.3 (4.5, 14.9)

5.4 (2.6, 10.9)

9.7 (5.4, 17.2)

Undifferentiated
(n = 117)

5.7 (2.4, 13.5)

1.9 (0.5, 7.4)

3.6 (1.1, 11.4) 3.6 (1.4, 9.3)

7.6 (3.9, 14.7)

8.4 (4.3, 16.0)

14.1 (8.4, 23.1)

1.9 (0.5, 7.2)

Growth delay: a decrease of 1.0 or more in height Z-score relative to the z-score of that child at enrolment. Short stature: a height below the 2.5th percentile for
age and sex. Excessive weight gain: an increase of 1.0 or more in BMI Z-score relative to the z-score of that child at enrolment. Obesity: a BMI above the 95th
percentile for age and sex
— = Cumulative incidence could not be calculated as no child had experienced the growth impairment at this time

only be confirmed by following healthy children at the
same time intervals and applying the 1.0 Z score cut-off;
we are not aware of any such study.
Defining growth impairments as a change of 1.0 Z
scores from baseline uses the child as his/her own control and allows identification of substantial changes in
growth that may not be apparent when using the extreme limits (e.g. below 2.5th percentile or above 95th
percentile). Nevertheless, some such changes may be desirable. For example, a child who is obese at baseline
may drop more than 1.0 BMI Z-scores in follow-up and
become closer to his/her ideal BMI (by our definition
this is “poor weight gain”).
Although the World Health Organization has proposed
standard terminology to describe growth impairments
[15], it has not been universally adopted. The recommended term for a stature <−2.0 Z-scores is ‘stunting’, but
we chose to use the term short stature instead, as we felt
the implication that 2.5% of healthy children have stunted
growth had overtly negative connotations. At the end, we
chose to use neutral descriptive terms and most importantly, we defined them explicitly.
The high prevalence and cumulative incidence of obesity
observed in our cohort may be a reflection of the current
epidemic of obesity among North American children. An

obesity point prevalence of 10.5 to 16.3% has been reported
among Canadian children aged 5 to 11 years old [24], and
new onset obesity has been reported in 11.9% of children in
the United States between the ages of 5 and 14 years old
[25]. However, children with systemic arthritis in our cohort had a three times higher incidence of obesity than
these reported population values.
There were some interesting differences across JIA categories in growth parameters at enrolment (Table 1).
These may reflect disease impact between symptom onset and enrolment, but they should be interpreted with
caution as chance alone may explain these differences.
One could postulate for example that the mean weight
Z-score of 0.31 at enrolment for the whole cohort represents the current obesity epidemic among Canadian children, and that the mean z-score of 0.16 for RF-positive
polyarthritis reflects weight loss during the nearly six
months from symptom onset, while the mean Z-score of
0.58 for systemic JIA reflects corticosteroid-associated
weight gain during the 2.9 months since symptom onset.
Again, one ought to be careful not to over-interpret
these differences given the large variability in growth parameters across children and small sample sizes in some
JIA categories in this cohort. Of note, children with
psoriatic arthritis had the highest mean weight Z-score
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Table 3 Impact of corticosteroid use, disease activity and covariates on height Z-scores and BMI Z-scores
Impact on height Z-scores
Unadjusteda
(95% CI)

Variable

Impact on BMI Z-scores

p value Adjusted
(95% CI)

Cumulative corticosteroidsb −0.69 (−0.82, −0.56) <0.01

p value Unadjusted
(95% CI)

p value Adjusted
(95% CI)

p value

−0.64 (−0.77, −0.50) <0.01

0.79 (0.63, 0.96)

<0.01

0.74 (0.56, 0.92)

<0.01

−0.02 (−0.03, −0.01) <0.01

−0.01 (−0.02, 0.00)

0.00 (−0.01, 0.01)

0.49

−0.01 (−0.02, 0.00)

0.17

Less than high school

Reference

Reference

High school/secondary

0.29 (−0.18, 0.77)

0.23

0.31 (−0.18, 0.80)

0.21

0.005 (−0.50, 0.51)

0.98

0.09 (−0.43, 0.61)

0.73

Some post-secondary

0.34 (−0.12, 0.80)

0.15

0.39 (−.08, 0.87)

0.11

−0.01 (−0.50, 0.48)

0.96

0.09 (−0.41, 0.60)

0.72

University degree

0.32 (−0.14, 0.78)

0.18

0.36 (−0.11, 0.84)

0.14

−0.17 (−0.66, 0.31)

0.49

−0.08 (−0.58, 0.43)

0.77

Postgraduate degree

0.40 (−0.08, 0.89)

0.10

0.43 (−0.07, 0.93)

0.09

−0.25 (−0.76, 0.26)

0.33

−0.11 (−0.64, 0.42)

0.68

Cumulative disease
activityc

0.04

Parental educationd
Reference

Reference

e

Primary Ethnicity
British

Reference

Reference

Reference

Reference

French

−0.09 (−0.26, 0.09)

0.32

−0.11 (−0.29, 0.07)

0.24

−0.36 (−0.55, −0.17) <0.01

−0.33 (−0.52, −0.13) <0.01

Indigenous Canadian

0.15 (−0.15, 0.45)

0.34

0.15 (−0.16, 0.46)

0.33

−0.05 (−0.37, 0.27)

−0.03 (−0.36, 0.30)

Other European

0.03 (−0.14, 0.19)

0.74

0.03 (−0.14, 0.20)

0.75

−0.31 (−0.49, −0.13) <0.01

−0.23 (−0.41, −0.05) 0.01

South Asian

0.33 (0.0, 0.66)

0.05

0.34 (0.0, 0.67)

0.05

−0.13 (−0.48, 0.22)

0.47

−0.13 (−0.49, 0.23)

0.48

Other

−0.07 (−0.27, 0.13)

0.47

−0.03 (−0.24, 0.18)

0.75

−0.23 (−0.44, −0.02) 0.03

−0.13 (−0.35, 0.09)

0.25

Oligoarthritis

Reference

Reference

RF-neg polyarthritis

−0.17 (−0.34, −0.01) 0.04

−0.14 (−0.32, 0.03)

0.10

−0.01 (−0.18, 0.17)

Enthesitis-related

0.17 (−0.01, 0.36)

0.21 (0.01, 0.40)

0.04

0.08 (−0.12, 0.27)

0.45

−0.04 (−0.25, 0.18)

0.74

Systemic

−0.36 (−0.61, −0.10) 0.01

−0.23 (−0.51, 0.05)

0.10

0.68 (0.41, 0.95)

<0.01

0.44 (0.15, 0.74)

<0.01

Psoriatic

0.04 (−0.23, 0.30)

0.79

0.16 (−0.12, 0.44)

0.26

0.41 (0.13, 0.69)

<0.01

0.31 (0.01, 0.61)

0.05

RF-pos polyarthritis

−0.13 (−0.46, 0.19)

0.43

−0.03 (−0.36, 0.31)

0.88

−0.13 (−0.47, 0.21)

0.46

−0.25 (−0.60, 0.10)

0.17

Undifferentiated

−0.18 (−0.39, 0.04)

0.11

−0.11 (−0.33, 0.12)

0.37

0.03 (−0.20, 0.25)

0.82

0.02 (−0.22, 0.26)

0.86

0.76

0.84

JIA categories

0.07

Reference

Reference
0.96

0.00 (−0.18, 0.19)

0.99

a

Unadjusted Beta coefficients and (95% CI) were obtained from mixed effect models including only one independent variable at a time. Adjusted beta coefficients
are from a mixed effects model where cumulative corticosteroids in previous 6 months, cumulative disease activity in previous 6 months, parental education,
ethnicity and JIA category were entered together. Cumulative prednisone and disease activity were time-variant variables. All mixed effects models were run by
subject and included random intercept, random slope and a quadratic term for time since diagnosis in weeks. They can be represented by: dependent variable = b1*constant + b2*time + b3*time square + b4* first independent variable + b5* second independent variable
b
Cumulative corticosteroids were calculated as area under the curve of daily prednisone equivalents per kilogram of body weight recorded at each clinic visit,
using the trapezoid method; a one unit change corresponds to an increase of 1 mg/Kg of prednisone equivalents per day sustained for 6 months. For the first
study visit, corticosteroids were assumed to start at diagnosis
c
Cumulative disease activity was calculated as area under the curve of the physician global assessment of disease activity recorded at each clinic visit, using the
trapezoid method; a one unit change corresponds to an increase of 1 cm in the physician global assessment sustained for 6 months. For the first study visit the
physician global assessment was assumed to be zero the day before disease onset
d
The level of education of the parent who had a higher level of education
e
The ethnic group listed first; up to six ethnic groups could be listed for each child as defined by Statistics Canada

of 0.66 at enrolment and they rarely, if ever, used
corticosteroids.
Two published retrospective cohorts are of particular relevance to our study. In a study of 67 Canadian children with
JIA, Liem and Rosenberg reported that relative to children
with oligoarthritis, a lower height Z-score was apparent in
the second year after diagnosis for children with systemic
arthritis [26]. A similar change was apparent from the first
year in our study. Children with RF-positive polyarthritis
tended to have negative Z-scores, while children with RFnegative polyarthritis tended to have positive Z-scores [26].
In our study, children with RF-negative polyarthritis had

practically normal growth while those with RF-positive polyarthritis had measurable, but mild growth impairments.
In the second study, Padeh et al. reported on 95 children with oligoarticular JIA in a single centre in Israel.
After a mean follow-up of 6 years they reported “severe
growth retardation” (a decrease in height Z-score of 1.0
or more relative to baseline) in 11.6% of children [10].
This estimate is compatible with our 3-year cumulative
incidence of growth delay of 7.8% using the same cutoff, but as stated above, we suspect this level of apparent
growth impairment reflects normal periods of relative
stasis and not true impairment.
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Recent studies suggest DMARDs and biologic agents
mitigate growth impairments in children with JIA [6, 7].
It is not clear whether this is due to better control of the
disease, reduced doses of corticosteroids, or both. One
non-controlled trial of anakinra monotherapy in systemic arthritis avoided use of corticosteroids in 13 of 20
children [27]. The 2013 update of the American College
of Rheumatology juvenile arthritis treatment recommendations includes initial monotherapy with biologics as an
option in children with systemic arthritis [28]. It will be
important to ascertain if early monotherapy with biologics prevents the growth impairments observed in patients with systemic JIA in our cohort.
Study strengths and limitations

To our knowledge, this is the largest prospective study of
growth in children with JIA published to date. It reflects
more recent treatment practices than previous studies and
we analysed growth in multiple ways to ensure our findings were robust. Nonetheless, our data should be interpreted in light of five limitations. First, although Z-scores
are age- and sex-standardized this may not fully adjust for
the effect of age and pubertal status on the child’s susceptibility to growth impairment, and we did not collect data
on pubertal status in this cohort. Second, because procedures to measure height and weight were not standardized
and the stadiometers and balances were not crosscalibrated, some differences in Z-scores may be due to
measurement variability. Third, cumulative corticosteroids
and cumulative disease activity in the previous 6 months
were based on few measurements, since we did not use
corticosteroid diaries and disease activity was only
assessed at clinic visits. Fourth, we did not report on localized growth impairments such as leg length discrepancy
or jaw asymmetry, which may occur in juvenile arthritis.
Finally, our estimates refer to 3 years after diagnosis, and
the risk of growth impairments may change with longer
follow-up. It is important to emphasize that the reported
growth impairments may be transitory and that final
height and weight may be normal due to catch up growth
and delayed puberty. Most children in this cohort had not
completed their growth at the last assessment, and we had
no parental height data to allow calculation of genetic
growth potential.
Implications for practice

Families of children with JIA should know that with
modern treatments, their child’s disease will not substantially affect growth and weight gain, unless the child
has systemic JIA, requires prolonged corticosteroid use
(>3 months) and/or has uncontrolled disease. Families of
children with systemic arthritis should know that systemic corticosteroids may control the disease, but at the
cost of potential growth impairment; a 1 in 10 risk of
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short stature and a 1 in 3 risk of obesity within 3 years
of diagnosis. Practitioners should be wary of prolonged
corticosteroid use and our results quantify their effect
on growth.

Conclusions
Most children with JIA in this cohort grew and gained
weight at a pace similar to modern North American populations. Children in the most frequent JIA categories grew
well, but about 1 in 10 children who had systemic
arthritis, uncontrolled disease activity, and/or required
prolonged use of systemic corticosteroids were at risk of
growth impairment. These children may benefit from earlier aggressive therapy to help prevent growth impairment,
or early consultation with a pediatric endocrinologist to
mitigate growth impairment by other means.
Additional file
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